Gebze

Prof.

Hale Başak Çağlar

She has been working as a radiation oncology expert and radiation oncology director at Anadolu Medical Center since 2017.

Radiation Oncology Department Oncology Center

Speciality

Varian Linear Accelerators (Trilogy
TrueBeam) CyberKnife (VSI
M6
MLC included) Gamma Knife (C and Perfexion models)

Education

University

Gazi University, Faculty of Medicine, Ankara 1998

Specialty Training

Marmara University, Faculty of Medicine, Radiation Oncology Department, İstanbul 2003

Assistant Professor

Marmara University, Faculty of Medicine, Radiation Oncology Department, İstanbul 2010

Professor

Medipol University, Faculty of Medicine, Radiation Oncology Department, İstanbul 2015

Institutions Worked At

Prof. Dr. Hale Başak Çağlar was born in Ankara on March 29th, 1975. She completed her primary and secondary education at TED Ankara College in between 1981-1992. She completed her education at the Faculty of Medicine / Gazi University in between 1992-1998, and finalized her specialization education at the Radiation Oncology Department / Marmara University in between 1998-2003 with her thesis, titled “Acute skin and pulmonary radiation toxicities in breast cancer patients treated with radiotherapy in the adjuvant setting”. She worked at the Brachytherapy Unit / Radiation Oncology Department / Faculty of Medicine / Hacettepe University in 2003; at the Radiation Oncology Department / Faculty of Medicine / Marmara University in between 2003-2009; at Harvard Joint Committee / Dana Farber Cancer Institute / Brigham and Maternity Hospital, Harvard University in between 2006-2007. She served as a Assistant Professor at the Radiation Oncology Department / Faculty of Medicine / Marmara University in between 2008-2010, and in the Faculty of Medicine / Acıbadem University in between 2010-2013. While she served as the Chairwoman and Program Director at the Radiation Oncology Department / Faculty of Medicine / Medipol University in between 2013-2015, she further served thereat as the Chairwoman, Program Director, and Professor until 2017. Having started working at the Anadolu Medical Center in 2017, Prof. Dr. Çağlar has been going on serving as a radiation oncology specialist and radiation oncology director since then.

ASTRO (American Society for Theurapetic Radiation Oncology)
ESTRO (European Society for Theurapetic Radiation Oncology)
EORTC (European Organisation for Research and Treatment of Cancer)
Radiosurgery Society (Board of Director)
Turkish Lung Cancer Society
Turkish Radiaiton Oncology Society
Turkish Medical Associaiton
Turkish Oncology Society

Scientific Projects:

1. Management of Anemia Under Radiochemotherapy (MARCH): An Open Randomized, Multicenter Study of the Effect of NEORECORMON on Treatment Outcome in Patients with Advanced Cervical Cancer Stage IIB-IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) MO16375. International, Multicentric, Co-Investigator.

2. Kemik Metastazlı Meme Kanserinde Zoledronik Asit Tedavisi Alan Hastalarda Tam Doz Veya Azaltılmış Doz Radyoterapinin Araştırılması (A Randomized Phase IV exploratory trial comparing full dose radiotherapy versus reduced dose in the management of bone metastasis in breast cancer receiving zoledronic acid) Randomized, phase III, multicentric, CZOL446ETR01, National, Co-Investigator.

3. p53 Polimorphisms and Haplotypes in Breast Cancer, Breast Cancer Research Group Study (MEKAG), Co-Investigator

4. A Double Blind, Placebo Controlled, Parallel Group, Multicenter, Randomised Phase III Survival Study Comparing ZD1839 (IRESSATM) (250 mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients with Advanced NSCLC Who Have Received One or Two Prior Chemotherapy Regimens and are Refractory or Intolerant to Their Most Recent Regimen, Co-Investigator

5. FACT: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade with Anastrozole and Fulvestrant Combination Therapy: An Open Randomized, Comparative, Phase III Multicentre Study in Postmenopausal Women with Hormone Receptor Positive Breast Cancer in First Relapse After Primary Treatment of Localised Tumour, Co-Investigator

6. Anastrazol Kullanan Erken Evre Meme Kanseri Hastalarında Elektronik Farmakovijilans Çalışması (Anastrazol monotherapy in early stage breast cancer, electronical farmacovigilance study), National, Co-Investigator.

7. Rekürren Yüksek Dereceli Glial Tümörlerde Standart Doz Temozolomide Sonrasında Progresyon Gelişiminde Uzamış Temozolomide Şeması Etkinlik Araştırılması (Efficacy of a protracted dose dense temozolamide schedule in patients with progression after standart dose temozolomide for recurrent high grade gliomas), national, Co-Investigator.

8. No Radiotherapy Versus Whole Brain Radiotherapy for 1 to 3 Brain Metastases From Solid Tumour After Surgical Resection or Radiosurgery, A Randomized Phase III Trial, EORTC Protocol 22952-26001, International, Multicentric, Co-Investigator.

9. -EULINT1. International Prophylactic Cranial Irradiation Trial. A Multicenter Randomized Trial of High Versus Standard Doses of Prophylactic Cranial Irradiation in Limited Small Cell Lung Cancer Complete Responders, EORTC Protocol 22003-08004, International, Multicentric study, Co-Investigator.

10. AMAROS After Mapping of the Axilla: Radiotherapy or Surgery, EORTC protocol 10981-22023, International, Multicentric study, Co-Investigator.

11. SUPREMO A Phase III Randomized Trial to Assess the Role of Adjuvant Chest Wall Irradiation in “Intermediate Risk” Operable Breast Cancer Following Mastectomy, EORTC Protocol 22051-10052, International, Multicentric study, Co-Investigator.

12. Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. EORTC Protocol 26053-22054. International, Multicentric study, Co-Investigator.

13. Adjuvant Postoperative High-dose Radiotherapy for Atypical and Malignant Meningioma: A Phase-II and Observation Study. EORTC protocol 22042-26042 International, Multicentric study, Co-Investigator.

14. Meme Kanseri Tanısı ile Takip Edilen Hastalarda Kemik Metastazının Görülme Sıklığını, Tanı Yöntemlerini ve Tedavi Yaklaşımlarını Değerlendiren Gözlem Çalışması, ZO-SAFE. (The frequency, diagnostic tools used and treatment modalities of bone metastatic breast cancer: an observation study ZO-SAFE). Protokol no: CZOL446ETR02, National, Multicentric study, Co-Investigator.

15. A Multinational, Randomized, Double-blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-line Docetaxel After Failure of one Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). VITAL EFC10261. International, Multicentric study, Co-Investigator.

16. Hormon Reseptörü Pozitif Opere Postmenopozal Meme Kanserli Hastaların Erken Adjuvan Tedavisinde Aromataz İnhibitörü Kullanımının Güvenliliği ve Nüks Paterni Üzerine Etkileri, ERADA. (Aromatase inhibitors in the adjuvant treatment of hormone receptor positive breast cancer: Implications on safety on recurrence patterns, ERADA). Protokol no: CFEM345DTR002. National, Multicentric study, Primary Investigator.

17. Akciğer Kanseri Nedeniyle Eş Zamanlı Kemoradyoterapi + Oral Glutamin Uygulanan Hastalarda Yaşam Kalitesi Değerlendirmesi. (Concuurent chemoradiation + oral glutamine in locally advanced lung cancer: a quality of life study). Primary Investigator.

Publıcatıons

A. International journals :

A1. Yumuk PF, Abacioglu U, Caglar H, Gumus M, Sengoz M, Turhal NS. Outcome of Rectal and Sigmoid Carcinoma Patients Receiving Adjuvant Chemoradiotherapy in Marmara University Hospital. J. Chemotherapy, 15(6), 603-606, (2003).

A2. Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H, Sengoz M, Turhal S. What is the optimal number of lymph nodes dissected in colorectal cancer surgery? Tumori (91:168-172, 2005)

A3. Abacioglu U, Yumuk PF, Çağlar H, Sengoz M, Turhal NS. Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer. BMC Cancer, Vol 5:71, 2005.

A4. Caglar H, Allen AM. Intensity Modulated Radiotherapy for Head and Neck Cancer. Clinical Advances in Hematology & Oncology. 2007 Jun;5(6):425-31.

A5. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AG, Evman S, Yuksel M. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008 May;3(5):499-504.

A6. Caglar HB, Tishler RB, Othus M, Burke E, Li Y; Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. November 2008;72(4):1110-1118.

A7. Demiral AN, Alicikus ZA, Ugur VI, Karadogan I, Yoney A, Andrieu MN, Yalman D, Pak Y, Aksu G, Ozyigit G, Ozkan L, Kilciksiz S, Koca S, Caloglu M, Yavuz AA, Caglar HB, Beyzadeoglu M, Igdem S, Serin M, Kaplan B, et al. Patterns of Care for Lung Cancer in Radiation Oncology Departments of Turkey. Int J Radiat Oncol Biol Phys. 72(5):1530-1537, May 2008.

A8. Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, Demirkalem P, Abacioglu U, Sengoz M, Sav A, Ozer A. Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer. Pathology and Oncology Research, (Epub ahead of print), (2008).

A9. Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM. Outcomes of Patients with Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery. Cancer, 2009 Sep 23;115(18):4156-4166.

A10. Basaran G, Devrim C, Caglar HB, Gulluoglu B, Kaya H, Seber S, Korkmaz T, Telli F, Kocak M, Dane F, Yumuk FP, Turhal SN. Clinical outcome of breast cancer patients with N3a (>/=10 positive lymph nodes) disease: has it changed over years? Med Oncol. 2011 Sep;28(3):726-32.

A11 Abacioglu U, Caglar H, Atasoy BM, Abdulloev T, Akgun Z, Kilic T. Gamma knife radiosurgery in non small cell lung cancer patients with brain metastases: treatment results and prognostic factors. J BUON. 2010 Apr-Jun;15(2):274-80.

A12 Alexander BM, Othus M, Caglar HB, Allen AM. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1381-7

A13 Caglar HB, Othus M, Allen AM. Esophagus in-field: a new predictor for esophagitis. Radiother Oncol. 2010 Oct;97(1):48-53.

A14 Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol. 2010 Sep 29. [Epub ahead of print].

A15 Atasoy BM, Dane F, Uçüncü Kefelı A, Cağlar H, Cıngı A, Turhal NS, Abacioğlu U, Yeğen C. Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer. Turk J Gastroenterol. 2011 Feb;22(1):60-4.

A16 Allen AM, Albert M, Caglar HB, Zygmanski P, Soto R, Killoran J, Sun Y. Can Hyperpolarized Helium MRI add to radiation planning and follow-up in lung cancer? J Appl Clin Med Phys. 2011 Jan 31;12(2):3357.

A17 Midi A, Belirgen M, Caglar H, Sav A. Investigation of The Effect of Radiotherapy on The Proliferative Index (Ki-67) in Recurring Diffuse Glial Tumors. Journal of Neurological Sciences (Turkish), 28(1).

A18 Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, Igdem S, Caglar H, Ozsaran Z, Lössl. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e757-63.

A19 Ozyar E, Caglar HB, Atalar B. In regard to Zhou et al "Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis" (Int J Radiat Oncol Biol Phys 2012;82:e359-e365). Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):482-3.

A20 Lyatskaya Y, Rehfeld K, Kadam DV, Caglar H, Allen A, Chin LM, Killoran JH. Comparison of two techniques for target motion evaluation based on 4DCT images. International Journal of Biomedical Engineering and Technology 8.2-3 (2012): 117-137.

A21 Atalar B, Gungor G , Caglar H, Aydin G, Yapici B, Ozyar E. Use of volumetric modulated arc radiotherapy in patients with early stage glottic cancer. Tumori 2012, 98(3):331-336.

A22 Atalar B, Caglar H, Ozyar E. Stereotactic Radiotherapy of Primary Lung Cancer and Other Targets: Results of Consultant Meeting of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys 2011; 79: 660–669.

A23 Bozcuk H, Abali H, Coskun S; Lung Cancer Committee of Turkish Oncology Group. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World J Surg Oncol. 2012 Aug 9;10(1):161.

A24 Atalar B, Aydin G, Gungor G, Caglar H, Yapici B, Ozyar E. Dosimetric comparison of robotic and conventional linac-based stereotactic lung irradiation in early-stage lung cancer. Technol Cancer Res Treat. 2012 Jun;11(3):249-55.

A24 Erpolat OP, Alco G, Caglar HB, Igdem S, Saran A, Dagoglu N, Aslay I, Ozsaran Z, Demirci S, Keven E, Guney Y, Akmansu M, Kilic D, Bayman E, Etiz D, Mandel NM. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study. Eur J Gynaecol Oncol. 2014;35(1):62-6.

A25 Mahadevan A, Bucholz R, Gaya AM, Kresl JJ, Mantz C, Minnich DJ, Muacevic A, Medbery C 3rd, Yang J, Caglar HB, Davis JN. Best of the Radiosurgery Society® Scientific Meeting 2014: stereotactic radiosurgery/stereotactic body radiotherapy treatment of extracranial and intracranial lesions. Future Oncol. 2014 Dec;10(15):2307-10.

A26 Batırel HF, Metintaş M, Caglar HB, Ak G, Yumuk FP, Yıldızeli B, Yüksel M, Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy. J Thorac Cardiovasc Surg. 2016 Feb;151(2):478-84.

A27 Zwahlen DR, Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, Igdem S, Caglar H, Ozsaran Z, Loessl K, Belkaaloul KK, Villette S, Vees H. Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study. Rare Tumors. 2016 Jun 29;8(2):6052.

A28. Acar H, Altinok AY, Kucukmorkoc E, Caglar M, Sut PA, Kucuk N, Doyuran M, Caglar HB. "Dosimetric Comparison of IMRT and VMAT Techniques using RTOG 0631 Guidelines in Spine Sterotactic Body Radiosurgery." Cancer ResOncol 2, no. 007 (2016).

B. International Proceedings

B1. Çağlar H, Abacıoğlu U, Arıbal E, Şengöz M, Çetin İ, Güllüoğlu B. Survival Comparison and Characteristics of Adjuvantly Irradiated Breast Cancer Patients Diagnosed with Lump in Breast or Screening Mammogram. The Breast Journal 2001; Vol 7(5) Suppl:41, OP-76.

B2. Şengöz M, Çağlar H, Abacıoğlu U, Atasoy B, Turhal S, Güllüoğlu B. Patient Characteristics and Treatment Results of Postoperatively Irradiated Breast Cancer Patients. The Breast Journal 2001; Vol 7(5) Suppl:42, OP-77.

B3. Caglar H, Sengoz M, Abacioglu U, Kodalli N. The Early Treatment of Radiation Pneumonitis in Patients After Adjuvant Radiotherapy for Breast Cancer. European Journal of Cancer. Vol 37 (Supp. 6); S184-185, 2001.

B4. Gumus M, Aliustaoglu M, Atalay G, Macunluoglu B, Dane F, Caglar HB, Sengoz M, Turhal NS. The Extension of Nodal Sampling in Colorectal Cancer Patients in Marmara University Hospital, Istanbul. Proc Am Soc Clin Oncol 21: 2002 (abstr 2345)

B5. Caglar H, Abacioglu U, Turhal S, Sengoz M. Gemcitabine (GEMZAR) as a Radiosensitizer in Stage III Non Small Cell Lung Cancer. The Fourth Annual Global Oncology Young Investigators’ Meeting, Abstract Book, Lilly Oncology, Indianapolis, 2002.

B6. Abacioglu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS. Results of Concurrent Chemoradiotherapy (CRT) With Low Dose Weekly Gemcitabine (G) in Stage III Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7318

B7. Abacioglu MU, Akgun Z, Caglar H. Factors Affecting Brain Metastases Development in Stage III Non Small Cell Lung Cancer Patients Treated With Definitive Treatment. 25th ESTRO Annual Meeting, Leipzig, Radiother Oncol, Vol. 81 (Suppl. 1), S388, 2006.

B8. Basaran GA, Cabuk D, Caglar HB, Iyikesici S, Tebessum Ç, Gulluoglu B, Kaya H, Dane F, Yumuk PF, Turhal NS. Stage I (T1N0M0) Breast Cancer (BC): Pathological Characteristics and Clinical Outcome. 31st ESMO Congress, Istanbul, Ann Oncol, Vol. 17 (Suppl. 9), ix113, 2006.

B9. Dane F, Gumus M, Yumuk PF, Iyikesici S, Ozturk A, Basaran G, Caglar HB, Cabuk D, Teomete M, Turhal NS. Outcome of Colon Cancer Patients Receiving Adjuvant Chemotherapy in Marmara University Hospital. 31st ESMO Congress, Istanbul, Ann Oncol, Vol. 17 (Suppl. 9), ix130, 2006.

B10. Teomete M, Yumuk PF, Iyikesici MS, Dane F, Basaran G, Cabuk D, Caglar HB, Abacioglu U, Turhal NS. Outcome of Patients With Stage III and IV Non-Small Cell Lung Cancer in Marmara University Hospital, Istanbul, Turkey. 31st ESMO Congress, Istanbul, Ann Oncol, Vol. 17 (Suppl. 9), ix225, 2006.

B11. Dane F, Topaloglu N, Abul Y, Yumuk PF, Turhal NS, Ceyhan B, Celikel T, Caglar H, Basaran G, Ahiskali R. Interstitial Penumonitis Associated with Docetaxel Administration. 31st ESMO Congress, Istanbul, Ann Oncol, Vol. 17 (Suppl. 9), ix307, 2006.

B12. Ozen Z, Caglar H, Akgun Z, Abacioglu U. Three dimensional non coplanar irradiation for right hemithoracic tumors of operated malignant mesothelioma. Radiotherapy and Oncology, Volume 84, Supplement 1, P S275 (September 2007).

B13. Caglar HB, Allen AM, Burke E, Posner M, Haddad R, Norris C, Annino D, Wirth L, Tishler R. Swallowing Function After Intensity Modulated Radiotherapy (IMRT) and Chemotherapy for Head and Neck Cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 6046.

B14. Caglar HB, Allen AM, Othus M, Li Y, Burke E, Wirth L, Gougen LA, Haddad RI, Posner MR, Tishler RB. Dose to the Larynx Predicts for Swallowing Complications Following IMRT and Chemotherapy. International Journal of Radiation Oncology, Biology, Physics 2007, Vol. 69, Issue 3, S53-S54.

B15. Allen AM, Othus M, Baldini EH, Mentzer SJ, Bueno R, Sugarbaker DJ, Colson YL, Marcoux JP, Johnson BE, Caglar HB. Prognostic factors for radical treatment of stage III NSCLC. European J Cancer Supp, September 2007, Volume 5, Issue 4,392 Abstract No 6613.

B16. Caglar HB, Mentzer S, Lukanich JM, Janne PA, Marcoux PJ, Lathan C, Rabin MS, Colson YL, Allen AM. Full Dose Chemoradiation Followed by Surgical Resection in Locally Advanced NSCLC. 12th World Conference on Lung Cancer. Journal of Thoracic Oncology, Volume 2, Number 8, Supplement 4, S635, P2-166, August 2007.

B17. Yumuk PF, Teomete M, Dane F, Cabuk D, Caglar HB, Abacioglu U, Basaran G, Turhal NS. Outcome of Patients With Stage III and IV Non-Small Cell Lung Cancer in Marmara University Hospital, Istanbul, Turkey. 12th World Conference on Lung Cancer. Journal of Thoracic Oncology, Volume 2, Number 8, Supplement 4, P2-323, August 2007.

B18. Caglar HB, Othus M, Allen AM. Mean In-field Esophagus Dose Predicts for Esophagitis in Lung Cancer Patients Treated with 3D-CRT and Concurrent Chemotherapy. International Journal of Radiation Oncology, Biology, Physics 2008 Vol. 72, Issue 1, Supp 1, S427, 2578.

B19. Allen AM, Sun Y, Caglar HB, Zygmanski P, Killoran JH, Albert M. Hyperpolarized Helium MRI and the Importance of Ventilation Tumor Volumes (VTVs) Before and After RT for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 2008, Vol. 72, Issue 1, Supp 1, S626, 3017.

B20. Basaran G, Caglar H, Bese N, Haydaroglu A, Eralp Y, Abali H. Clinical Outcome of T1N0 Breast Cancer (BC) Patients (pts): A Turkish Oncology Group Retrospective Analysis. Journal of BUON, Proceedings, October 2008.OP-21

B21. Abacioglu U, Caglar HB, Yumuk F. Efficacy of Protracted Dose-Dense Temozolomide in Patients With Progressive High-Grade Glioma, Schering-Plough Temodal International Research Update Meeting, Cenevre, 11-12 Nisan 2008.

B22. Alexander BA, Othus M, Caglar HB, Allen AM. Mediastinal Nodal Volume Predicts For Survival In Stage III NSCLC. Journal of Thoracic Oncology 2008, vol 3(11), supp 4, Abstract No 118.

B23. Abacioglu U, Kefeli A, Akgun Z, Caglar H, Atasoy B, Yumuk F, Kilic T. Single Center Survival Outcomes of 167 Glioblastoma Patients: Before and After Temozolomide. The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology Abstract Book, May 2008, 167, P107.

B24. Abacioglu MU, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M. Efficacy of Protracted Dose-dense Temozolomide (TMZ) in Patients With Progressive High-grade Glioma. J Clin Oncol June 2009, Volume 27, 18S, e13018.

B25. Ozen Z, Unal S, Caglar H, Akgun Z. Postmastectomy Radiation Therapy: Dosimetric Differences of Automatic Bolus by Treatment Planning System. Radiotherapy and Oncology, Volume 92, Supplement 1, Pages S251 (August 2009)

B26. Schick U, Bolukbasi Y, Abdah-Bortnyak R, Thariat J, Caglar H, Ozsaran Z, Lössl K, Zwahlen D, Villette S, Vees H.Outcome and pronostic factors in malignant Mixed Mullerian Tumours and endometrial stromal sarcomas: a rare cancer network study. European J Cancer Supp, September 2009, Volume 7, Issue 2, 459 Abstract No 8031.

B27. Abacioglu M, Akgun Z, Kefeli AU, Atasoy BM, Caglar HB. Effect of time interval between surgical resection and radiotherapy on survival of patients with glioblastoma. International Journal of Radiation Oncology, Biology, Physics November 2009, Vol. 75, Issue 3, Supp 1, S229, 2106.

Caglar, Hale B., Esra Kucukmorkoc, Ayse Altinok, Nadir Kucuk, Mine Doyuran, and Hilal Acar. The Effect of Adaptive Planning on Target and Critical Structures During Radiation Treatment for Locally Advanced Lung Cancer. Journal of Thoracic Oncology, vol. 10, no. 9, pp. S449-S449.

Yumuk PF, Besiroglu M, Dane F, Kanitez M, Aktas B, Caglar C, Yildizeli B, Dede F, Atasoy B, Turhal NS. Is PET/CT a better ttol than CT in response evaluation and follow up of stage III non-small cell lung cancer after chemoradiotherapy? Journal of Thoracic Oncologt, vol. 8, pp. S559-S559.

Altinok A, Doyuran M, Caglar M, Canoglu D, Kucukmorkoc E, Acar H, Kucuk N, Caglar H. Boost volume assessment in breast cancer: preop tumor volume vs clips used in oncoplastic surgery. Radiotherapy and Oncology April 2016 , Volume 119 , S566.

Pacaci P, Cebe MS, Mabhouti H, Codel G, Serin E, Sanli E, Doyuran M et al. "Dosimetric evaluation of the dose calculation accuracy of different algorithms for two different treatment techniques during whole breast irradiation." Physica Medica 32 (2016): 247.

Serin E, Codel G, Mabhouti H, Cebe M, Sanli E, Pacaci P, Kucuk N, Kucukmorkoc E, Doyuran M, Canoglu C, Altinok A, Acar H, Caglar HO. Accuracy of the Small Field Dosimetry Using the Monte Carlo and Sequential Dose Calculation Algorithms of Multiplan Treatment Planning System Within and Beyond Heterogeneous Media for Cyberknife M6 Unit. Physica Medica 32 (2016): 271.

Codel G, Serin E, Cebe MS, Mabhouti H, Pacaci P, Sanli E, Doyuran M, Kucukmorkoc E, Altinok A, Canoglu C, Kucuk N, Acar H, Caglar H. Accuracy of the small field dosimetry using Acuros XB and AAA dose calculation algorithms of eclipse treatment planning system within and beyond heterogeneous media for Trubeam 2.0 unit. Physica Medica: European Journal of Medical Physics, Volume 32, 271.

Mabhouti H, Sanli E, Cebe MS, Codel G, Pacaci P, Serin E, Doyuran M, Kucukmorkoc E, Altinok A, Canoglu D, Kucuk N, Acar H, Caglar H. The dosimetric comparison of Truebeam and Cyberknife treatment planning systems dose calculation accuracy for brain SRS treatment on Randophantom. Physica Medica Volume 32, Supplement 3, September 2016, Pages 273.

C. Internationsl book chapters :

Caglar, Hale Basak, et al. "and Branislav Jeremic." Decision Tools for Radiation Oncology: Prognosis, Treatment Response and Toxicity (2014): 91.

Caglar, Hale Başak. "Radiotherapy Options of Brainstem Tumors." Posterior Fossa Tumors in Children. Springer International Publishing, 2015. 595-608.

Caglar, Hale Basak. "Radiation Therapy in Atypical Teratoid/Rhabdoid Tumors." Posterior Fossa Tumors in Children. Springer International Publishing, 2015. 667-672.

Caglar, Hale Basak. Radiation Therapy of Malignant Pleural Mesothelioma. Malignant Pleural Mesothelioma: Present Status and Future Directions. DOI: 10.2174/9781681081946116010026

D. National journals :

D1. Çağlar HB, Abacıoğlu U. Evre I Seminomda Güncel Tedavi Yaklaşımları. Üroonkoloji Bülteni, 2, 7-11, (2006).

D2. Abacıoğlu U, Çağlar HB, Şengöz M. Trakea Tümörlerinin Tedavisinde Radyoterapi. Türkiye Klinikleri J Surg Med Sci, 2(29), 131-132 (2006).

D3. Batırel HF, Gemici C, Yıldızeli B, Laçin T, Akgül AG, Evman S, Çağlar HB, İlhan M, Yüksel M. Results of Transthoracic Esophagectomy Following Chemoradiation in Locally Advanced Esophageal Cancer. Turkish Journal of Cancer, 38(1): 20-25, 2008

D4. Atasoy BM, Dane F, Çağlar H, Tezcanlı E, Cingi A, Abacıoğlu U, Turhal S, Yeğen C. Rezeke Edilebilir Lokal İleri Evre Rektum Kanserinde Floroprimidin Bazlı Kemoterapi İle Eş Zamanlı Ameliyat Öncesi Radyoterapi. Türk Onkoloji Dergisi 2008;23(4):163-171.

Atalar B, Kucukmorkoc E, Doyuran M, Gungor G, Aydin G, Yapici B, Caglar H, Ozyar E. Comparisons of static 7 field and dynamic conformal arc techniques for stereotactic lung radiotherapy/Stereotaktik akciger isinlamalarinda statik 7 alan ve dinamik konformal ark tekniklerinin karsilastirilmasi. Turkish Journal of Oncology 27, no. 3 (2012): 111-119.

Çetin İA, Yumuk PF, Atasoy BM, Dane F, Çağlar HB, İbrahimov R. Batırel HF, Abacıoğlu U. Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz / Chemoradiotherapy Experience in Locally Advanced Esophageal Cancer. Marmara Medical Journal 2012;25:74-7

Caglar HB. Sağlıklı dokuyu koruyarak lokal kontrolü artırmak: Radyoterapide yeni teknikler. Sparing the healthy tissue while increasing the local control: New techniques in radiotherapy. doi:10.5152/pb.2011.15

E. National proceedings:

E1. Şengöz M, Abacıoğlu U, Atasoy B, Çağlar H, Çetin İ, Pamir N, Turkan S. Yüksek Grade’li Gliomalarda Radyoterapi Sonuçları ve Prognostik Faktörler. XIII. Ulusal Kanser Kongresi, Bildiri Özetleri Kitapçığı, s24, S95, Antalya, 1999.

E2. Atasoy B, Abacıoğlu U, Çağlar H, Çetin İ, Şengöz M. Beyin Metastazlarının Tedavisinde Palyatif Kraniyal Radyoterapi Sonuçları. IV. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, s113, P45, Bursa, 2000.

E3. Şengöz M, Baltalarlı B, Çetin İ, Abacıoğlu U, Şenkesen Ö, İşbakan Z, Atasoy B, Çağlar H, Turkan S. Definitif Radyoterapi Uygulanan Lokalize Prostat Kanserli Olgularda Biyokimyasal Nükssüz Sağkalım. 6. Ege Onkoloji Günleri – Ürogenital Kanserler Sempozyumu, Özet Kitapçığı, İzmir, 2001.

E4. Abacıoğlu U, Şengöz M, Çağlar H, Gümüş M, Atalay G, Turhal S. Rektum ve sigmoid Kanserlerinde Adjuvan Kemoradyoterapi Sonuçları. XIV. Ulusal Kanser Kongresi, Bildiri Özetleri Kitapçığı, s64, SB-07, İstanbul, 2001.

E5. Çağlar H, Şengöz M, Abacıoğlu U, Kodallı N. Adjuvan Radyoterapi Uygulanan Meme Kanseri Olgularında Gelişen Radyasyon Pnömonisinin Erken Tedavisi. XIV. Ulusal Kanser Kongresi, Bildiri Özetleri Kitapçığı, s88, SB-15, İstanbul, 2001.

E6. Şengöz M, Çağlar H, Abacıoğlu U, Atasoy B, Turhal S, Güllüoğlu B. Postoperatif Radyoterapi Uygulanan Meme Kanserli Hastalarımızın Özellikleri ve Tedavi Sonuçları. VI. Ulusal Meme Hastalıkları Kongresi, Meme Hastalıkları Dergisi, Cilt 8(3), s32, P62, İstanbul, 2001.

E7. Çağlar H, Abacıoğlu U, Arıbal E, Şengöz M, Çetin İ, Güllüoğlu B. Memede Kitle Veya Tarama Mamografisi ile Tanı Konulan Radyoterapi Uygulanmış Meme Kanserli Hastaların Dağılımı ve Sağkalım Karşılaştırması. VI. Ulusal Meme Hastalıkları Kongresi, Meme Hastalıkları Dergisi, Cilt 8(3), s32, P-63, İstanbul, 2001.

E8. Çağlar H, Abacıoğlu U, Turhal S, Şengöz M. Evre III Küçük Hücre Dışı Akciğer Kanseri Hastalarında Radyoterapi ile Eşzamanlı Gemsitabinin Radyoduyarlılaştırıcı Olarak Kullanılması. V. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitapçığı, s214, ATP-6, Kuşadası, 2002.

E9. Abacıoğlu U, Odabaş ÖF, Tezcanlı E, Çağlar H, Yumuk PF, Şengöz M, Turhal S. Kolorektal Kanserli Hastaların Yaşam Kalitesini Değerlendirmede EORTC Kolorektal Kanser Modülü QLQ-CR38’in Türkçe Çevirisi ve Pilot-Test Çalışması. VI. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı s161, P45, Antalya, 2004.

E10. Çağlar H, Abacıoğlu U, Tezcanlı E, Yumuk F, Turhal S, Şengöz M. Lokal İleri Evre Pankreas Kanserli Hastalarda Radyoterapi ve Eş Zamanlı Gemsitabin Tedavisinin Toksisite ve Sağkalım Sonuçları. VI. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, s164, P48, Antalya, 2004.

E11. Abacıoğlu U, Şengöz M, Tezcanlı E, Çağlar H, Yumuk PF. Yüksek Gradeli Nüks Gliomlarda Temozolomidin Tolerabilitesi ve Etkinliği. VI. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, s339, P223, Antalya, 2004.

E12. Sönmez Ö, Çağlar H, Demirkaya P, Kaya H, Akkiprikli M, Düşünceli F, Abacıoğlu U, Güllüoğlu B, Şengöz M, Özer A, Sav A. Meme Kanserinde p53 Geni 3. İntron Bölgesindeki 16 BP Duplikasyon Polimorfizm Sıklığı ve Prognozla İlişkisi. VI. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, s366, P250, Antalya, 2004.

E13. Çağlar H, Abacıoğlu U, Şengöz M. Meme Kanseri Nedeniyle Postoperatif Radyoterapi Uygulanan Hastalarda Görülen Erken Dönem Yan Etkilerin Hastaya Ve Tedaviye Bağlı Özellikler Açısından Değerlendirilmesi. VI. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, s370, P254, Antalya, 2004.

E14. Çağlar H, Abacıoğlu U, Şengöz M, Çamlıca H. Meme Kanseri Nedeniyle Postoperatif Radyoterapi Uygulanan Hastalarda Görülen Erken Dönem Cilt ve Akciğer Toksisiteleri ile Tamoksifen Zamanlamasının Değerlendirilmesi. VI. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, s371, P255, Antalya, 2004.

E15. Sönmez Ö, Abacıoğlu U, Akkiprik M, Kaya H, Demirkalem P, Çağlar H, Güllüoğlu MB, Sav A, Özer A. Meme Kanserli Türk Kadınlarında p53 İntron 3-16b Duplikasyon Polimorfizmi. VI. Ulusal Prenatal Tanı ve Tıbbi Genetik Kongresi, Bildiri Kitabı, 64-65, Antalya, 2004.

E16. Solmaz Ö, Demirkalem P, Çağlar H, Kaya H, Akkiprik M, Düşünceli F, Abacıoğlu U, Güllüoğlu BM, Şengöz M, Sav A, Özer A. Türk Toplumunda Sağlıklı Bireylerde ve Meme Kanseri Olan Hastalarda p53 Geni Polimorfizmi Sıklığı: Polimorfizm Varlığı Sağkalımı Etkiliyor mu? Ulusal Cerrahi Kongresi Özet Kitabı, s69, s-120 Antalya, Mayıs 2004.

E17. Kaya H, Erbarut İ, Güllüoğlu B, Çağlar H, Abacıoğlu U, Özkan N, Arıbal E. Memenin İnvaziv Duktal Karsinomlarında p53, ve c-erbB-2 Onkogenlerinin Ekspresyonunun Östrojen-Progesteron Reseptörleri ve Histopatolojik Parametrelerle İlişkisi. XVII Ulusal Patoloji Sempozyumu Bildiri Kitabı, s208, 1-6 Ekim 2004, Gaziantep.

E18. Akgün Z, Çetin İ, Karaüç G, Çağlar H, Abacıoğlu U, Dane F, Yumuk F, Şengöz M, Turhal S. Mide Adenokarsinomlarında Cerrahi Rezeksiyon Sonrasında Adjuvan Kemoradyoterapi Sonuçlarımız. XVI. Ulusal Kanser Kongresi, Bildiri Özet Kitabı, s38, ref 708, Antalya, 2005.

E19. Çetin İ, Akgün Z, Çağlar H, Tezcanlı E, Abacıoğlu U, Şengöz M, Yumuk F, Turhal S, Türkeri L. Mesane Tümörlü Hastaların Kemoradyoterapi Sonuçları. XVI. Ulusal Kanser Kongresi, Bildiri Özet Kitabı, s60-61 ref 806, Antalya, 2005.

E20. Zorlu F, Pak Y, Kurtman C, Akman F, Çağlar H, Okumuş NÖ, Koç M, Soyuer S, Hayran M. Türkiye’de Santral Sinir Sistemi Tümörlerinin Çok Merkezli Kesitsel İncelemesi: TOG – Santral Sinir Sistemi Alt Grubu. XVI. Ulusal Kanser Kongresi, Bildiri Özet Kitabı, s105, ref 818 Antalya, 2005.

E21. Tezcanlı E, Abacıoğlu U, Çağlar H, Yumuk F, Şengöz M. Yüksek Gradeli Nüks Gliomlarda Temozolomidin Tolerabilitesi ve Etkinliği. XVI. Ulusal Kanser Kongresi, Bildiri Özet Kitabı, s106, ref 631, Antalya, 2005.

E22. Güllüoğlu BM, Sarıkaya Ö, Dede F, Barlas A, Bayramiçli M, Çağlar H, Yumuk F, Başaran GA, Kaya H, Aktan AÖ. Marmara Üniversitesi Tıp Fakültesi Genel Cerrahi Uzmanlık Eğitimi İçerisinde Multidisipliner Meme ve Endokrin Cerrahisi Eğitimi; Eğitim Kalitesini ve Öğrenci Memnuniyetini Artırabilmek için bir Model. Ulusal Tıp Eğitimi Kongresi Özet Kitabı, s78, B12, Adana 2006.

E23. Akgün Z, Çağlar H, Abacıoğlu U, Şengöz M. Küratif Tedavi Uygulanmış Evre III Küçük Hücreli Dışı Akciğer Kanseri Hastalarında Beyin Metastazı Oluşumunu Etkileyen Faktörler. VII. Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, s85, P007, Fethiye, 2006.

E24. Topaloğlu N, Dane F, Balcı M, Abul Y, Golabi P, Yumuk P, Turhal S, Ceyhan B, Çelikel T, Karakurt S, Çağlar H, Ahıskalı R. Docetaxel’e Bağlı İntertistel Pnömonitis. Toraks Dergisi 2006;7(1):106, PS126.

E25. Batırel HF, Metintaş M, Yıldızeli B, Laçin T, Çağlar HB, Bostancı K, Akgül AG, Evman S, Yüksel M. Malign Plevral Mezotelyomada Trimodalite Tedavi Sonuçları. Toraks Dergisi 2007;8(2):166, TP 333.

E26. Çaglar HB, Allen A, Othus M, Burke E, Posner M, Tishler R. Baş boyun IMRT ve Kemoterapisi Sonrasında Yutma Güçlüğünü Etkileyen Dozimetrik Parametreler. VIII.Ulusal Radyasyon Onkolojisi Kongresi, Program, Bildiri ve Konuşma Özetleri Kitabı, s79, S0021, Antalya, 2008.

E27. Atasoy BM, Dane F, Çağlar H, Cingi A, Abacıoğlu U, Turhal S, Şengöz M, Yeğen C. Rezeke Edilebilir Lokal İleri Evre Rektum Kanserinde Preoperatif Radyoterapiyle Eşzamanlı Floroprimidin Uygulaması: Oral mi, İntravenöz mü? 8. Ulusal Radyasyon Onkolojisi Kongresi, Program, Bildiri ve Konuşma Özetleri Kitabı, s184, P0184, Antalya, 2008.

E28. Akgün Z, Atasoy B, Çağlar H, Çetin İ, Dane F, Abacıoğlu U. Anal Kanserlerde Definitif Tedavi Sonuçlarımız. 8. Ulusal Radyasyon Onkolojisi Kongresi, Program, Bildiri ve Konuşma Özetleri Kitabı, s190, P0200, Antalya, 2008.

E29. Sarıkaya Ö, Atasoy BM, Çağlar HB, Güllüoğlu B, Dede F, Öneş T, Yumuk F, Başaran G, Dane F, Abacıoğlu U. Probleme Dayalı Öğrenmede Performans Değerlendirme. V. Ulusal Tıp Eğitimi Kongresi Bildiri Özetleri Kitabı, s6, C8, İzmir, 2008.

E30. Çağlar HB, İğdem Ş, Tezcanlı E, Alço G, Kefeli AÜ, Atasoy BM, Dane F, Abacıoğlu U. Sınırlı Evre Küçük Hücreli Akciğer Kanserinin Multimodalite Tedavi Sonuçları ve Prognostik Faktör Analizleri. XVIII. Ulusal Kanser Kongresi, Program ve Bildiri Özet Kitabı, s4-5, S11, Antalya, 2009.

E31. Başaran G, Okkan S, Çağlar H, Benekli M, Haydaroğlu A, Eralp Y, Abalı H, Yıldız F, Beşe N, Gürsel B, Güney N, Derin D. HER-2 Ekspresyonu ve Hormon Reseptörleri Bilinen T1N0 Meme Kanserli (MK) Hastaların Retrospektif Analizi: Türk Onkoloji Grubu Çalışması. XVIII. Ulusal Kanser Kongresi, Program ve Bildiri Özet Kitabı, s 16, S39, Antalya, 2009.

E32. Kefeli AÜ, Akgün Z, Çağlar HB, Atasoy BM, Dane F, Yumuk PF, Kılıç T, Abacıoğlu U. Tek Merkezde Tedavi Edilen 167 Glioblastoma Tanılı Hastanın Sağkalım Sonuçları: Temozolomide Öncesi ve Sonrası. XVIII. Ulusal Kanser Kongresi, Program ve Bildiri Özet Kitabı, s18, S44, Antalya, 2009.

E33. Atasoy BM, Dane F, Akgün Z, Çabuk D, Kabalay İA, Yumuk F, Çağlar H, Turhal S, Abacıoğlu U. Lokal İleri Evre Nazofarenks Kanserinde Dosetaksel ile Sisplatin Bazlı İndüksiyon Kemoterapisi Sonrası Sisplatinle Eş Zamanlı Kemoradyoterapi:Sağkalım ve Yan Etki Değerlendirmesi. VIII.Ulusal Kanser Kongresi, Program ve Bildiri Özet Kitabı, s130, P236, Antalya, 2009.

E34. Akgün Z, Kefeli AÜ, Atasoy BM, Çağlar HB, Abacıoğlu U. Glioblastoma Hastalarında Cerrahi ile Radyoterapi Arası Sürenin Sağkalıma Etkisi. XVIII. Ulusal Kanser Kongresi, Program ve Bildiri Özet Kitabı, s134-135, P246, Antalya, 2009.

F. Citations:

F1. Gümüs M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H, Sengoz M, Turhal S. What is the optimal number of lymph nodes dissected in colorectal cancer surgery? Tumori (91:168-172, 2005) 8 atıf.

- GJ Chang GJ, Rodriguez-Bigas MA, Skibber JM et al. Lymph Node Evaluation and Survival After Curative Resection of Colon Cancer: Systematic Review. J Natl Cancer Inst. 2007;99:433-41.

- Koppie TJ, Vickers AJ, Vora K et al. Standardization of pelvic lymphadenectomy performed at radical cystectomy. Can we establish a minimum number of lymph nodes that should be removed? Cancer 2006;107(10):2368-74.

- Greco P, Andreola S, Magro G, et al. Potential pathological understaging of pT3 rectal cancer with less than 26 lymph nodes recovered: a prospective study based on a resampling of 50 rectal specimens. Virchows Arch 2006;449:647-651.

- Govindarajan A, Baxter NN. Lymph Node Evaluation in Early-Stage Colon Cancer. Clinical Colorectal Cancer 2008;7(4):240-246.

- Dillman RO, Aaron K, Heinemann KS, et al. Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performance. Cancer 2009;115(9):1840-1848.

- Trueman P, Lowson K, Bending M, et al. Bowel Cancer Services: Costs and Benefits. Lterature Review. Yorl Health Economics Consortium 2007:1-359.

- Norwood MGA, Sutton AJ, West K et al. Lymph node retrieval in colorectal cancer resection specimens: National standards are achievable, and low numbers are associated with reduced survival. Colorectal Disease 2009, epub.

- Martínez-Ramos D, Escrig-Sos J, Miralles JM, et al. Is there a minimum number of lymph nodes that should be examined after surgical resection of colorectal cancer? Cir Esp. 2008 Mar;83(3):108-17.

F2. Abacioglu U, Yumuk PF, Çağlar H, Sengoz M, Turhal NS. Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer. BMC Cancer, Vol 5:71, 2005. 1 atıf.

- Choi B, Robins HI, Schiller J et al. A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer. Cancer Chemother Pharmacol 2008;63:175-179.

F3. Caglar H, Allen AM. Intensity Modulated Radiotherapy for Head and Neck Cancer. Clinical Advances in Hematology & Oncology. 2007 Jun;5(6):425-31. 5 atıf.

- Simo R, Morgan P, Jeannon JP, et al. Integrated media presentation in multidisciplinary head and neck oncology meetings. Eur Arch Otorhinolarngol 2009;266:261-265.

- Diaz R, Blakey MD, Murphy PD, et al. Thyroid Storm After Intensity-Modulated Radiation Therapy: A Case Report and Discussion. Oncologist 2009;14:233-239.

- Kim M, Ghate A, Phillips MH, et al. A Markov decision process approach to temporal modulation of dose fractions in radiation therapy planning. Phys. Med. Biol 2009;54:4455-4476.

- Diaz R, Jaboin JJ, Morales-Paliza M, et al. Hypothyroidism as a Consequence of Intensity-Modulated Radiotherapy with Concurrent Taxane-Based Chemotherapy for Locally Advanced Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys 2009, epub.

- Salama J, Haddad R, Kies M, et al. Clinical Practice Guidance for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys 2009;75 (3):725-733.

F4. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AG, Evman S, Yuksel M. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008 May;3(5):499-504. 9 atıf.

- Krug LM, Pass HI, Rusch VW, et al. Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma. J Clin Oncol 2009 Jun 20;27(18):3007-13.

- Ramalingam SS, Belani CP. Recent Advances in the Treatment of Malignant Pleural Mesothelioma. J Thorac Oncol. 2008 Sep;3(9):1056-64.

- McAleer MF, Tsao AS, Liao Z. Radiotherapy in Malignant Pleural Mesothelioma. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):326-37.

- Buduhan G, Menon S, Aye R, et al. Trimodality Therapy for Malignant Pleural Mesothelioma. Ann Thorac Surg. 2009 Sep;88(3):870-5.

- Trousse DS, Avaro JP, D'Journo XB, et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg. 2009 Oct;36(4):759-63.

- Zona A, Bruno C. Health surveillance for subjects with past exposure to asbestos: from international experience and Italian regional practices to a proposed operational model. Ann Ist Super Sanità 2009 Vol. 45, No. 2: 147-161.

- Ak G, Metintas S, Metintas M, et al. Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma. J Thorac Oncol 2009, epub.

- A Hasani, JM Alvarez, JM Wyatt, et al. Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia. J Thorac Oncol 2009;4(9):1010-1016.

- Batırel HF. Malign Plevral Mezotelyomada Trimodalite Tedavi. Türk Toraks Derneği, Plevra Bülteni, Ocak 2009; 3(1):19-29.

F5. Caglar HB, Tishler RB, Othus M, Burke E, Li Y; Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. November 2008;72(4):1110-1118. 7 atıf.

- Caudell JJ, Schaner PE, Desmond RA, et al. Dosimetric Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2009, epub.

- Langendijk JA, Bijl HP. Late Radiation-Induced Side Effects. Functional Preservation and Quality of Life in Head and Neck Radiotherapy, ed: P. M. Harari, N. P. Connor and C. Grau, Springerlink, 2009.

- N Platteaux, P Dirix, E Dejaeger, et al. Dysphagia in Head and Neck Cancer Patients Treated with Chemoradiotherapy. Dysphagia 2009, epub.

- Caudell JJ, Burnett III OL, Schaner PE, et al. Comparison of Methods to Reduce Dose to Swallowing-Related Structures in Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2009, epub.

- Rancati T, Fiorino C, Sanguineti G. NTCP Modeling of Subacute/Late Laryngeal Edema Scored by Fiberoptic Examination. Int J Radiat Oncol Biol Phys. 2009;75(3):915-23.

- Popovtzer A, Cao Y, Feng FY, et al. Anatomical changes in the pharyngeal constrictors after chemo-irradiation of head and neck cancer and their dose–effect relationships: MRI-based study. Radiother Oncol 2009, epub.

- Yang ES, Murphy BM, Chung CH, et al. Evolution of clinical trials in head and neck cancer. Crit Rev Oncol Hematol. 2009 Jul;71(1):29-42.

F6. Demiral AN, Alicikus ZA, Ugur VI, Karadogan I, Yoney A, Andrieu MN, Yalman D, Pak Y, Aksu G, Ozyigit G, Ozkan L, Kilciksiz S, Koca S, Caloglu M, Yavuz AA, Caglar HB, Beyzadeoglu M, Igdem S, Serin M, Kaplan B, et al. Patterns of Care for Lung Cancer in Radiation Oncology Departments of Turkey. Int J Radiat Oncol Biol Phys. 2008;72(5):1530-1537. 2 atıf.

- Kepka L, Casas F, Perin B, et al. Radiochemotherapy for Lung Cancer in Developing Countries. Clinical Oncology 2009;21:536-542.

- Tomita N, Kodaira T, Hida T, et al. The Impact of Radiation Dose and Fractionation on Outcomes for Limited-Stage Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2009, epub.

Areas of Interest

Radiation Therapy: What Is It, How Is It Done, and What Are Its Side Effects?

Radiation therapy, also known as radiotherapy, is a treatment commonly preferred for cancer patients, utilizing high-energy beams to kill cancer cells.

What is Cancer Treatment? How is Cancer Treatment Done?

All tissues and organs in the body are made up of different types of cells. Over time, new cells formed by the division of healthy cells replace the cells that die. This process of cell renewal continues throughout a person's life. The timing of when cells should multiply is controlled by DNA. Due to DNA damage, cells may begin to divide unnecessarily. Cancer, one of today's serious diseases, is a condition that arises from the uncontrolled multiplication of the body's own cells.

Bone Tumors

A tumor is a mass or swelling that arises from the uncontrolled division of body cells, resulting in growth within the affected tissue and/or organ. The cause of most bone tumors is unknown. As the tumor grows, it gradually spreads to healthy tissues, causing them to be replaced by abnormal tissues and weakening the bone, which can lead to pathological fractures. If necessary precautions are not taken, aggressive tumors can cause functional deficiencies within the organ system they develop in and may even threaten life by affecting the entire body's metabolism.

Cancer Pain

Cancer pain can arise from various causes such as the destruction of normal tissues due to cancer, circulatory disorders caused by blockages in blood vessels, bone fractures related to metastases, infections, inflammation, pressure from the tumor on nerves, or blockages in hollow organs or various channels. It can also result from pain that occurs in the body due to cancer treatment methods such as surgery, chemotherapy, and radiation therapy.

Kidney Cancer Symptoms and Treatment Methods

What is Pancreatic Cancer and How is the "Whipple Surgery" Applied in the Treatment Process?

Pancreatic cancer is one of the most common types of cancer. What is pancreatic cancer, what are its symptoms, and what is done in treatment? How is the "Whipple technique," one of the most difficult surgeries in the field of general surgery, applied?

What is Ovarian (Ovary) Cancer, Its Symptoms, and Treatment

Ovarian cancer is a type of tumor that occurs due to the uncontrolled growth and proliferation of cells in the ovarian or fallopian tube tissue. Ovarian cancer, also known as ovary cancer, is among the most common cancers faced by women worldwide. Diagnosing it can sometimes be difficult because symptoms often develop in the later stages. This can prevent early detection. Commonly experienced symptoms of ovarian cancer can include pelvic pain, abdominal pain, bloating, abnormal bleeding, or vaginal discharge. The goal of ovarian cancer treatment is to remove the tumor from the body. Treatment methods include surgery, chemotherapy, targeted therapy, and radiotherapy.

What is Immunotherapy? How is Immunotherapy Applied?

There are ongoing developments in cancer treatment every day. In addition to chemotherapy and radiotherapy methods that have been used for many years, immunotherapy, a type of treatment using drugs, has begun to provide longer-lasting control over cancer in recent years. By activating a person's immune system, immunotherapy enables the individual's own immune cells to fight cancer cells more effectively.

What is Cancer? Diagnosis and Treatment Methods

Cancer is a disease that results from the uncontrolled multiplication and growth of cells in any organ or tissue of the body. It is named according to the tissue in which it occurs. More than 200 types have been identified. The most common and fatal types of cancer are lung, stomach, liver, colon, and breast cancer. If cancer spreads from its original site to other organs and tissues, this is called metastasis.

Types of Skin Cancer, Diagnosis, and Treatment Processes

Skin cancer occurs when DNA damage arises in the cells of the skin and this damage is not repaired, leading to uncontrolled proliferation of the damaged cells. More than 99% of skin cancers are composed of three types of cancer.

What Are the Symptoms, Causes, and Treatment of Laryngeal Cancer?

Laryngeal cancer, also known as throat cancer, is a significant health issue that affects the respiratory tract. The larynx is an organ that plays a crucial role in breathing and sound production. This type of cancer can lead to the uncontrolled proliferation of cells within the larynx, which can spread and result in severe health problems if left untreated.

What is Liquid Biopsy? How is Liquid Biopsy Performed?

Cancer is one of the significant health problems threatening human health today, and extensive efforts are being made to find a solution. Despite various diagnostic and treatment methods used so far, an effective method for curing cancer has not yet been established. For this reason, numerous research studies on cancer are being conducted internationally, utilizing various technologies for diagnosis and treatment. One of these methods is liquid biopsy.

Palliative Care: What Is It, How Is It Received, and What Are Its Conditions?

Palliative care is highly effective in reducing the negative impacts experienced by patients and their families during the lifelong treatment process and in alleviating complications related to the disease, thereby improving the quality of life.

What Is Lung Cancer? Symptoms and Treatment

Lung cancer, which ranks first among cancer diseases that lead to death worldwide, is a significant public health issue that causes the death of over 1.7 million people each year. The symptoms and signs that appear in the early stages of the disease are often unnoticed, and critical symptoms like coughing, especially in smokers, are largely overlooked. This situation leads to lung cancer being detected at very late stages, significantly reducing the chances of treatment. Having accurate information about lung cancer, being able to recognize early symptoms, and regularly participating in screening programs in the presence of risk factors are crucial for properly diagnosing and treating lung cancer.

Leukemia (Blood Cancer): What Is It, What Are Its Symptoms, Diagnosis, and Treatment Methods?

Leukemia, commonly referred to as blood cancer, is one of the most prevalent types of cancer. It originates from the bone marrow and the lymphatic system. While some types are primarily seen in children, there are also various types that occur in adults. Early diagnosis is crucial in leukemia, just as it is for all types of cancer. Although leukemia involves a complex treatment process, advancements in methods and strategies are progressively improving outcomes.

Symptoms and Treatment Methods of Lymph (Lymphoma) Cancer

The lymphatic system, also known as the lymph or lymphoid system, is associated with both the circulatory and immune systems. This system, which consists of lymph nodes and a network of lymph vessels, circulates a fluid called lymph, made up of blood plasma and white blood cells. These white blood cells play a role in immunity by fighting disease-causing agents. Lymph nodes act as filters, cleaning out foreign disease agents and providing protection against infections and other diseases. Lymphoma, or lymph cancer, occurs due to the uncontrolled growth and proliferation of lymphocytes, the primary cells of the lymphatic system. This disease, which shows varying symptoms depending on the area of involvement, is most commonly found in the lymph nodes.

Cervical Cancer: Symptoms, Types, and Treatment

Cervical cancer is one of the most common types of cancer in women. Every year in our country, thousands of women are diagnosed with cervical cancer, and thousands of women lose their lives due to cervical cancer. It is possible to prevent deaths due to cervical cancer with vaccination and screening.

Vulvar Cancer: What It Is, Types, Symptoms, Diagnosis, and Treatment

Vulvar cancer refers to malignant tumor formations that can arise on the external surface of the female genital organs. The vulva includes the clitoris and the vaginal lips, known as labia, as well as the skin surrounding the urethra (urinary canal) and vagina. Vulvar cancer often presents as a mass or ulcer that causes itching in the vulva. It can occur at any age but is most frequently diagnosed in older adults. The treatment for vulvar cancer typically involves surgery to remove the cancerous tissue along with a small amount of surrounding healthy tissue. Sometimes, this surgery may require the complete removal of the vulva. The earlier the diagnosis, the less likely it is that extensive surgery will be needed. Therefore, early diagnosis and treatment are crucial.

What is Cervical Cancer?

Human papillomavirus (HPV) is a double-stranded DNA virus. Approximately 630 million women worldwide are currently infected with HPV, which is transmitted through sexual contact. Unlike other sexually transmitted diseases, HPV can also be transmitted through skin-to-skin contact without direct penetration during sexual intercourse. Therefore, the protective effect of condoms is limited. The Center for Disease Control (CDC) in the USA reports that 50% of sexually active men and women will encounter HPV at some point in their lives. A population-based study in the USA found that one in four sexually active women tested positive for HPV DNA.

What Are the Symptoms and Treatment Methods of Testicular Cancer?

Testicles are essential organs of the male reproductive system, located in a skin sac called the scrotum behind the penis. They produce and store sperm and produce the main sex hormone, testosterone. Testicular cancer occurs due to uncontrolled growth and proliferation of cells within the testicles, forming tumors. It is one of the most common reproductive system cancers in men. Although it can progress without symptoms for a long time, it has one of the highest treatment success rates, making early diagnosis crucial.

What Are the Symptoms of Prostate Cancer? Stages and Treatment

The prostate gland is an organ of the male reproductive system, located just below the bladder, with its base in contact with the bladder, and has a pyramidal structure. The prostate surrounds the prostatic urethra, which is the channel responsible for the flow of urine from the bladder. In males who have not yet reached puberty, the prostate weighs about 2 grams, but it grows with age, reaching up to 20 grams in adult males before the age of 52. The prostate is a gland that plays a significant role in male fertility. Its primary function is to produce the fluid that nourishes sperm and ensures their protection within the seminal fluid. Prostate cancer is the uncontrolled division, proliferation, and growth of cells within the prostate gland, leading to cancer. Since prostate cancer often does not show symptoms in its early stages, diagnosis can be delayed, increasing the likelihood of metastasis.

Symptoms, Diagnosis, and Treatment Process of Bladder Cancer

Bladder cancer is the second most common cancer occurring along the urinary tract, starting from the kidneys. Approximately two-thirds of bladder cancers are non-fatal but tend to recur, while one-third have the potential to invade muscle tissue and subsequently metastasize to the rest of the body, exhibiting a more aggressive course.

Soft Tissue Cancer (Sarcoma): Definition, Symptoms, Types, and Treatment

Soft tissue cancer, known in medical terms as sarcoma, is a type of malignant tumor that forms in connective tissues and is a rare type of cancer. Soft tissues are those that support, connect, or surround organs in the body, including muscle, blood vessels, nerves, tendons, and the inner lining of joints. Sarcomas can occur in childhood, young adults, and older adults. This cancer type may present as a lump or mass that can be felt in soft tissues. While sarcomas can occur anywhere in the body, they most commonly develop in the arms, legs, and abdominal region. These masses can be either painful or painless. A definitive diagnosis of soft tissue cancer is made through a biopsy, which helps determine the treatment plan. Depending on the progression of the disease, treatment options may include surgical interventions, radiation therapy, chemotherapy, or targeted therapy.

Bone Cancer: What Is It, Types, Symptoms, Diagnosis, and Treatment

Many areas of the human body are conducive to tumor formation, one of which is the bones that cover a large part of the body. Tumors can arise from uncontrolled cell divisions occurring in the bones. If these tumors are malignant, it is referred to as bone cancer. The most common symptom of bone cancer is pain caused by the spread of the tumor or the fracture of a weakened bone due to a tumor. Additionally, there may be a feeling of stiffness and tenderness in the bone. Other symptoms such as fatigue, fever, swelling, and stumbling may also occur, but these can be caused by other conditions as well. The diagnosis of bone cancer is made through tests performed by a doctor.

Gallbladder Cancer Symptoms, Causes, and Treatment

The gallbladder is an organ that is part of the digestive system and plays a role in producing bile, which is necessary for fat metabolism. The gallbladder, which stores and secretes bile, is located in the upper right part of the abdomen. Due to various reasons, changes can begin to occur in the cells of the gallbladder, and these cellular changes may lead to the development of cancer. Gallbladder cancer, which can present with symptoms such as abdominal pain and bloating, is a serious medical condition that requires intervention.

Liver Cancer

Malignant tumor formations developing within the liver are referred to as liver cancer. The liver is the largest internal organ of the body. It is responsible for performing many vital functions, including the removal of various wastes from the body, absorption of various nutrients, and wound healing. Located in the upper right part of the abdominal region, the liver is also responsible for bile production.

Nasopharyngeal Cancer: Symptoms, Causes, and Treatment

Nasopharyngeal cancer is a common subtype of head and neck cancers. These cancers differ significantly from other head and neck malignancies in terms of their etiology, epidemiology, histopathology, biological behavior of the disease, and treatment. Therefore, nasopharyngeal cancers should be considered separately from other head and neck malignancies. This type of cancer is difficult to diagnose early, and its treatment typically involves radiotherapy and chemotherapy.

What is Pharynx or Throat Cancer? Symptoms and Treatment Process

The pharynx, or throat, is located behind the nasal and oral cavities. Its upper part is connected to the nasal cavity (nasopharynx), while its lower part (hypopharynx) continues to the esophagus. Throat cancers include cancers of the base of the tongue, uvula, tonsil tissue, and the back walls of the throat. Oropharyngeal and hypopharyngeal cancers are considerably rarer than nasopharyngeal cancers. Worldwide, an estimated 123,000 new cases of oropharyngeal and hypopharyngeal cancers are diagnosed annually.

Tongue Cancer: What It Is, Symptoms, Types

Tongue cancer is one of the types of oral cancer that develops from the cells found in all areas of the tongue. This condition can lead to the formation of tumors, growths, and lesions in the mouth. Tongue cancer is divided into different subtypes depending on which part of the tongue it develops in. These subtypes have their own specific symptoms. The most common symptom of tongue cancer is the presence of non-healing sores on the tongue. While tongue cancer is more commonly seen in older individuals, there has been a recent increase in cases among younger and middle-aged individuals. With early diagnosis and treatment, tongue cancer can be managed and treated effectively.

Head and Neck Cancers: What They Are, Causes, Symptoms, and Treatment

Head and neck cancers refer to the uncontrolled and abnormal growth of cancer cells in the head and neck area of the body. Early diagnosis and treatment of head and neck cancers are crucial. While these cancers can be treated successfully in many cases, they can also cause permanent damage in some situations. To prevent such damage, various treatment methods can be applied to eliminate the cancer cells or halt their progression.

Oral Cancer: What It Is, Causes, Symptoms, and Treatment

Oral cancer is a global health problem and ranks second in frequency among head and neck cancers in our country, with developed countries being the most affected. As with many conditions, early diagnosis and treatment are crucial for this type of cancer. Oral cancer, which is classified under head and neck cancers, refers to cancers that develop in any part of the mouth area, including the inside of the cheeks and gums. This malignant tumor, also known as oral cancer, typically originates from the squamous (flat) cells in the mouth, tongue, and lips. To learn more about this cancer type, you can continue reading the article.

What is Rectal Cancer? What Are the Symptoms of Rectal Cancer?

The rectum is the last 15 cm of the muscular channel called the colon, which is an important part of the digestive system. Tumor cells that develop in this 15 cm area may lead to rectal cancer once they reach a certain number. It is a type of cancer with a high mortality rate, which is why early diagnosis and treatment are critical. Rectal cancer may develop without symptoms in some cases. Some patients may experience symptoms such as rectal bleeding, diarrhea, constipation, and unexplained weight loss. A family history of rectal cancer and certain hereditary disorders may increase the risk of rectal cancer. Treatment procedures may vary depending on the stage of the cancer. The general treatments include surgery, chemotherapy, radiation therapy, and targeted therapy.

Symptoms and Treatment Methods of Pancreatic Cancer

Pancreatic cancer is a condition that affects the pancreas, an organ located in the abdominal region that helps with digestion. Symptoms may include nausea, bloating, fatigue, jaundice, and loss of appetite. Treatment methods include surgery, chemotherapy, and radiation. Due to the difficulty of detecting the disease in its early stages, it can lead to serious complications.

What is Stomach Cancer? What are Its Symptoms and Treatment?

Stomach cancer is a type of cancer that occurs due to the uncontrolled growth and multiplication of cells lining the surface of the stomach. It can form at the junction of the esophagus and stomach or in the body of the stomach. Compared to other cancers, it develops more slowly.

Skin (Dermal) Cancer: What It Is, Symptoms, Diagnosis, and Treatment

Skin cancer, contrary to popular belief, is a common type of cancer. Research has shown that nearly one in five people will develop skin cancer at some point in their lives (1). Moreover, if diagnosed early, the disease can be completely treated. Common treatment methods include excision, cryotherapy, chemotherapy, radiation, and Mohs surgery. Appropriate treatments can be applied based on the type or stage of the disease. In some cases, a combination of several treatment methods may be used. Early diagnosis is crucial for complete treatment, so it is important to pay attention to any changes in the skin. To avoid skin cancer, it is important to have a dermatology check-up at least once a year.

What is Thyroid Cancer? What are the Symptoms of Thyroid Cancer?

Thyroid cancer is an uncontrolled cell growth that starts in the thyroid gland and has many types. While most types grow slowly, some can be aggressive. This type of cancer may not cause any symptoms in its early stages; however, as the cancerous tissue grows, it can lead to symptoms such as swelling in the neck, changes in voice, and difficulty swallowing. Thyroid cancers account for approximately 1% of all cancers【1】. In recent years, the incidence has increased particularly among the female population. Imaging methods may be used during the diagnosis stage. Most thyroid cancers can be treated with various procedures, and the types of cancer that respond best to treatment are small tumors in the early stages.

Symptoms, Diagnosis, and Treatment Methods of Breast Cancer

Breast cancer is the most common cancer among women and the leading cause of cancer-related deaths. It accounts for 24% of all female cancers and 15.5% of cancer deaths. It is reported that 1 in 8 women will be diagnosed with breast cancer at some point in their lives. Rarely, breast cancer is also seen in men, with 1 man diagnosed for every 100 women. The incidence of breast cancer has been found to increase every year.

Lipoma: Symptoms, Causes, Treatment

The skin is an organ that protects the body against external factors such as heat, light, microorganisms, and injury. Acting as a vital barrier for organs, the skin helps maintain body temperature, receive various signals from the environment, and provide immune system defense. The thickness and texture of the skin can vary among individuals. However, all humans have skin composed of three layers. The outermost layer of the skin is the epidermis, which contains melanocytes that give color to the skin. Beneath the epidermis lies the dermis, which houses sebaceous glands, hair follicles, nerve endings, and sweat glands. The innermost layer, the hypodermis, is a fatty tissue where body fat is stored. Each layer can have different functions. The sebaceous glands in the dermis are small glands that help reduce fragility by covering hair follicles. The lumps that occur due to the excessive growth of cells in this fatty tissue are called lipomas. Lipomas can form in any area where fat cells are present, and they are generally benign and usually harmless. Known as "lipomas," these lumps are painless, mobile, and fatty. They typically occur in adults aged 40-60 years. The formation of cancerous lipomas is rare and is referred to as "liposarcoma." Dermiste bulunan yağ bezleri kıl köklerini kaplayarak kırılganlığı azaltmaya yardımcı olan küçük bezlerdir. Bu yağ dokusundaki hücrelerin aşırı şekilde büyümeleri sonucu oluşan yumrulara yağ bezesi denir. Yağ hücrelerinin bulunduğu her bölgede oluşabilen yağ bezesi iyi huylu ve genellikle zararsızdır. “Lipom” olarak bilinen yağ bezeleri ağrısız, hareketli ve yağlı yumrular şeklindedir. Genellikle 40-60 yaş yetişkinlerde görülebilir. Kanserli lipom oluşması nadirdir ve “liposarkom” olarak adlandırılır (1, 2).

Staging of Breast Cancer

There are 4 stages in breast cancer. These are:

What is Lymphoma? How is Lymphatic Cancer Treated?

Lymphoma is a general term that describes cancers originating from the lymphatic system, which is part of the immune system. Lymphomas are commonly known as lymph node cancers, but the disease can also occur in organs without involving the lymph nodes.

Screening Methods in Breast Cancer

The high prevalence of breast cancer, its increasing frequency, the possibility of treating it in its early stages, and the ability to diagnose it at an early stage under current conditions all increase the importance of screening methods for breast cancer.

What Are the Symptoms of Childhood Cancer?

Certain types of cancer are more prevalent in childhood. Early detection of these cancers is more likely when families are aware of the symptoms. Cancers detected early are easier to treat and have less chance of spreading.

Esophageal Cancer Symptoms and Treatment

Esophageal cancer is a condition that affects the esophagus, the long, muscular tube that carries food from the throat to the stomach. Symptoms are often not noticeable until the cancer has spread, making early detection challenging. The most common types are squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma typically develops in the upper part of the esophagus, while adenocarcinoma usually occurs in the lower part. Symptoms may include difficulty swallowing, pain, weight loss, indigestion, and esophageal blockage. Risk factors include chronic reflux disease, obesity, and certain dietary habits. With early diagnosis, doctors can successfully intervene with surgery and other treatments

Brain Cancer: What It Is, Symptoms, Diagnosis, and Treatment

Brain cancer is the rapid and uncontrolled multiplication and growth of malignant tumor cells in the brain. The cells responsible for brain cancer have the ability to self-renew. Brain tumors can occur in the pituitary and pineal glands, the membrane on the surface of the brain, and the nerves. Secondary tumors, which originate in other parts of the body and spread to affect the brain, are more common than primary brain tumors that arise directly in the brain. The most commonly observed cases of brain cancer originate from secondary brain tumors. In 2022, it was reported that more than 1,900 people, with an average age of 59, were diagnosed with brain cancer worldwide.

Featured Cancer Articles